author-photo

Miwako Kobayashi

National Center for Immunization and Respiratory Diseases

13

Papers

168

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions.

2021 Human Vaccines & Immunotherapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction.

2021 Vaccine
Show All
- Source
- Cite
- Save
Citations (0)
Occupational Respiratory Infections.

2020 Clinics in Chest Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Symptoms in blastomycosis, coccidioidomycosis, and histoplasmosis versus other respiratory illnesses in commercially insured adult outpatients, United States, 2016-2017.

2020 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (4)
Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.

2019 Vaccine
Show All
- Source
- Cite
- Save
Citations (14)
Severe human metapneumovirus and group A Streptococcus pneumonia in an immunocompetent adult

2019 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (2)
Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001–2015

2018 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (18)
Health worker adherence to malaria treatment guidelines at outpatient health facilities in southern Malawi following implementation of universal access to diagnostic testing

2017 Malaria Journal
Show All
- Source
- Cite
- Save
Citations (25)
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries

2016 F1000Research
Show All
- Source
- Cite
- Save
Citations (55)
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries [version 1; referees: 2 approved]

2016
Show All
- Source
- Cite
- Save
Citations (0)